Drug intelligence / Profile preview

amitriptyline

Development stage
Approved
Lead developer
Merck
Modality
Small Molecules
Administration
Oral, Intramuscular, Topical
01

Overview

Amitriptyline is a tricyclic antidepressant primarily used to treat major depressive disorder. It is also indicated for neuropathic pain syndromes (such as post-herpetic neuralgia), migraine and tension headache prophylaxis, and sometimes for eating disorders or nocturnal enuresis in children. Amitriptyline works by increasing the levels of certain neurotransmitters in the brain—mainly serotonin and norepinephrine—which helps regulate mood and pain perception[2][4][6]. The drug has strong anticholinergic effects, which contribute to its sedative properties but also increase side effects such as dry mouth, drowsiness, constipation, and weight gain[2][7]. Due to its side effect profile and toxicity risk in overdose, it is generally considered a second-line therapy for depression and pain conditions[2].

Brand names
ElavilEndepVanatrip
Other names
阿米替林
02

Targets

ADRA1A (α1A)ADRA2A (α2A)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)NMDAR (Glutamate receptor ionotropic, NMDA)NET (Norepinephrine Transporter)MOR (Mu opioid receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on amitriptyline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amitriptyline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call